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a  b  s  t r  a  c  t
Cisplatin  is  a  widely  used  anti-cancer  drug.  Ototoxicity  is a major  dose-limiting  side-effect.  A  reproducible
mammalian  in-vitro  model  of  cisplatin  ototoxicity  is required  to screen  and  validate  otoprotective  drug
candidates.  We  utilized  a whole  organ  culture  system  of  the  postnatal  mouse  inner  ear  in  a  rotating
wall  vessel  bioreactor  under  “simulated  microgravity”  culture  conditions.  As  previously  described  this
system  allows  whole  organ  culture  of the inner  ear  and  quantitative  assessment  of  ototoxic  effects  of
aminoglycoside  induced  hair  cell loss.  Here  we demonstrate  that  this  model  is  also  applicable  to  the
assessment  of cisplatin  induced  ototoxicity.  In this  model  cisplatin  induced  hair  cell  loss was  dose  and
time  dependent.  Increasing  exposure  time  of  cisplatin  led to  decreasing  EC50 concentrations.  Outer  hair
cells were  more  susceptible  than  inner  hair cells,  and  hair  cells  in  the  cochlear  base  were  more  susceptiblergan culture
air cell loss
rgan of Corti
than  hair  cells  in the  cochlear  apex.  Initial  cisplatin  dose  determined  the ﬁnal  extent  of hair  cell loss
irrespective  if the  drug  was  withdrawn  or continued.  Dose  dependant  otoprotection  was  demonstrated
by  co-administration  of  the antioxidant  agent  N-acetyl  l-cysteine.  The  results  support  the  use  of  this
inner  ear  organ  culture  system  as  an  in vitro  assay  and  validation  platform  for inner  ear  toxicology  and
the  search  for otoprotective  compounds.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
In a recent survey of the International Agency for Research on
ancer 3.2 million cases of cancer were newly diagnosed in the
uropean countries (Ferlay et al., 2010). In the treatment of can-
er, cisplatin [cis-Diammin dichloroplatinum (II)] has remained
n effective and widely used anti-cancer drug since it was ﬁrst
ntroduced to the clinic in the early 1970s. Applications include
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y-nc-nd/3.0/).a widespread range of cancers in children and adults. Adverse side-
effects of cisplatin include nephrotoxicity, bone marrow toxicity,
gastrointestinal toxicity, liver toxicity and neurotoxicity (Ekborn
et al., 2003). Beside these, one of the major dose-limiting side effects
is ototoxicity, often resulting in irreversible sensorineural hear-
ing loss. For example, 20% of testicular cancer patients treated at
standard dose experience persistent ototoxicity but it may  affect
more than 50% of patients receiving cumulative high doses of cis-
platin > 400 mg (Bokemeyer et al., 1998). Up to 60% of paediatric
cancer patients treated with cisplatin develop permanent bilat-
eral hearing loss (Knight et al., 2005, 2007; Brock et al., 2012).
In children, young age, male gender and increasing cumulative
dose appear as critical risk factors for cisplatin induced ototoxicity
(Yancey et al., 2012).
Cisplatin induced ototoxicity in the mammalian inner ear
has been described and modelled in numerous animal studies
(reviewed in: Rybak et al., 2007, 2009, 2012; Rybak and Ramkumar,
2007; Rybak and Whitworth, 2005; Schacht et al., 2012). In the
cochlea cisplatin causes degeneration of three different types of
cells; the hair cells in the organ of Corti (Anniko and Sobin, 1986;
Fleischman et al., 1975; Zheng and Gao, 1996) the epithelial cells of
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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he stria vascularis (Meech et al., 1998; Ravi et al., 1995) and neu-
ons of the spiral ganglion (van Ruijven et al., 2005; Zheng and Gao,
996; Zheng et al., 1995). A more profound toxic effect of cisplatin
n SGN than on hair cells was found in experiments with cochlear
xplant cultures (Zheng and Gao, 1996). It is generally accepted
hat cisplatin ototoxicity in hair cells is mediated by reactive oxy-
en species (ROS) (Clerici et al., 1996; Dehne et al., 2001; Kim et al.,
010; Rybak, 2007; Rybak et al., 2009; Rybak and Ramkumar, 2007).
ranscription factor NF-B and high-mobility group (HMG) protein
Rybak and Ramkumar, 2007), transcription factor STAT1 (STAT;
ignal transducers and activators of transcription) (Kaur et al., 2011;
chmitt et al., 2009) and Nox3 (Rybak et al., 2012) are suggested
s further death pathways. Currently, large scale drug screening
or otoprotective agents in in vivo animal models is impeded by
he mortality related to the systemic toxicity of cisplatin and the
nter-individual variability of the observed ototoxic effects partic-
larly in mice (Parham, 2011). Furthermore, the number of animals
ecessary to fully evaluate the number of potential ototoxic and
toprotective agents is prohibitive. Towards the development of an
n vivo model a quantitative assay employing the non-mammalian
odel of the lateral line of zebraﬁsh larvae has successfully been
ntroduced to facilitate drug screening for ototoxic and otoprotec-
ive agents (Chiu et al., 2008; Hirose et al., 2011a; Ou et al., 2007;
on and Parng, 2005). Hit compounds identiﬁed in the zebraﬁsh
creening system need to be validated in mammalian in vitro
odels.
Mammalian in vitro models to study cisplatin ototoxicity have
tilized inner ear cell lines, tissue culture and to a certain extent
hole organ culture. Immortalized cell lines have been generated
rom the auditory sensory epithelia of the H-2Kb-tsA58 trans-
enic mouse (Jat et al., 1991) at embryonic (Rivolta et al., 1998),
ostnatal (Kalinec et al., 2003) and functionally mature, adult-
ike (Kalinec et al., 1999) developmental stages. These cell lines
ave been employed for several purposes including the screen-
ng for toxic and protective agents (Kalinec et al., 2003; Rivolta
nd Holley, 2002). Tissue culture of isolated tissue fragments dis-
ected from the postnatal inner ear has been used extensively
or the study of cisplatin ototoxicity (Ding et al., 2011; Liu et al.,
998; Park et al., 2009; Previati et al., 2007; Yarin et al., 2005;
hang et al., 2003). However, tissue culture models require micro-
issection of the auditory sensory epithelium which is technically
emanding and time-consuming and puts a limit to its applica-
ion as a validation tool for the increasing number of potential
totoxic and otoprotective agents that arise from the increasing
umber of screening efforts using inner ear derived cell lines or
he zebraﬁsh lateral line. Finally, organ culture models used for
he study of cisplatin ototoxicity have been limited to develop-
ental stages of the late embryonic inner ear (Anniko and Sobin,
986).
In the present study we utilized our recently developed whole
rgan culture model of the postnatal inner ear in a rotating
ioreactor culture system under “simulated microgravity” con-
itions (Arnold et al., 2010; Hahn et al., 2008). This system
llows maintaining the entire mouse inner ear organ isolated
t postnatal day 7 for up to seven days in vitro culture (Hahn
t al., 2008). Here we demonstrate that in this model ototoxi-
ity can be quantitatively assessed for cisplatin and also serve
s a validation platform for otoprotective compounds such as
he antioxidant agent N-acetyl l-cysteine (l-NAC). l-NAC is in
linical use for many years (review: Samuni et al., 2013). It is fre-
uently prescribed as a mucolytic and antioxidative agent, due
o its rapid reactions with oxygen and thiyl radicals. l-NAC has
ecently (Riga et al., 2013; Yoo et al., 2013) been tested clini-
ally in patients receiving cisplatin treatment. It was shown that
-NAC was at least a promising drug to prevent cisplatin-induced
totoxicity.tters 227 (2014) 203–212
2. Material and methods
2.1. Animals
Mice used this study were obtained from an in house breeding
colony of either a 129SV (cisplatin ototoxicity) or NMRI (otopro-
tection) genetic background. Both mice strains gave similar results
regarding cisplatin ototoxicity. One hundred ﬁfty six animals were
used in this study. Animal use for organ explantation was approved
by the Committee for Animal Experiments of the Regional Council
(Regierungspräsidium) of Tübingen (dated 19 October 2010 and 06
November 2012).
2.2. Organ culture system setup
Details of the methods were described previously (Arnold
et al., 2010; Hahn et al., 2008). Brieﬂy, inner ear organ explants
were obtained from mice aged postnatal day 7 and 5–6.5 g body-
weight. Whole organ inner ear explants were cultured in 55 ml
High Aspect Ratio Vessel (HARV; Synthecon Inc., Houston, TX,
USA) culture vessels mounted on a Rotary Cell Culture System
(RCCSTM-4; Synthecon Inc., Houston, TX, USA). All dissections were
carried out under sterile conditions in a laminar ﬂow cell cul-
ture hood (HeraSafe KS12, Heraeus Instruments GmbH, Hanau,
Germany). Mice pups at postnatal day 7 were decapitated. The
complete inner ear bony labyrinth capsules were dissected from
the skull base in ice-cold Hank’s balanced saline solution (HBSS).
After completion of the gross dissection, a micro-dissection open-
ing the perilymphatic ﬂuid spaces was  carried out in order to
provide access of the culture medium to the inner ear sensory
epithelia. The bioreactor was placed in a 37 ◦C, humidiﬁed 5%
CO2/95% air incubator (HeraCell CO2 Incubator, Heraeus Instru-
ments GmbH, Hanau, Germany). Each incubator was installed
with one RCCSTM-4 allowing the culture of up to four culture
vessels in parallel in one incubator. Freshly dissected inner ear
organ explants were inserted into the HARV culture vessels and
suspended in cell culture medium. The HARV vessel was  run-
ning at a rotation speed of 30 rounds/min (RPM). The culture
medium was  Neurobasal® Medium (Life TechnologiesTM, Darm-
stadt, Germany) supplemented with 1× B27® supplement (Life
TechnologiesTM, Gibco®, Darmstadt, Germany) 5 mM glutamine
(Life TechnologiesTM, Invitrogen, Inc., Darmstadt, Germany), 10 mM
Hepes (Life TechnologiesTM, Invitrogen, Inc., Darmstadt, Germany),
and 100 U of penicillin (Sigma, St. Louis, MO,  USA).
2.3. Application of cisplatin
Cisplatin (MW:  300.05 g/mol, Sigma–Aldrich, St. Louis, MO,
USA; thus 1 g/ml = 3.3 M)  was applied to the culture medium
at different concentrations (up to 30 g/ml, corresponding to
approx. 99 M)  for 24, 48 or 96 h. In detail, concentrations used
for 24 h were 1, 2.5, 5, 10, 15 and 30 g/ml (corresponding molar
concentrations: 3.3, 8.25, 16.5, 33, 49.5 and 99 M),  for 48 h 0.1,
0.3, 0.5, 1, 1.5, 1.75, 2, 2.5, 3 and 5 g/ml (corresponding molar
concentrations: 0.33, 0.99, 1.65, 3.3, 4.95, 5.77, 6.6, 8.25, 9.9 and
16.5 M)  and for 96 h 0.1, 0.3, 0.5, 1 and 2 g/ml (corresponding
molar concentrations: 0.33, 0.99, 1.65, 3.3, and 6.6 M).
2.4. Application of l-NACThe otoprotective compound l-NAC (N-acetyl-l-cysteine;
Sigma–Aldrich, St. Louis, MO,  USA) (Feghali et al., 2001; Ton and
Parng, 2005) was applied at a concentration of 0.1, 0.3, 1 and 3 mM.
For this series of experiments separate controls were made without
logy Letters 227 (2014) 203–212 205
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Table 1
Survival of inner (IHC) and outer (OHC) hair cells after 24, 48 and 96 h in culture.
Level denotes the cisplatin concentration (g/ml), N the number of organ explants.
Mean values (Mean) and standard deviation (Std Dev) are given.
Level (g/ml) N IHC OHC
Mean Std Dev Mean Std Dev
24 h Cisplatin
0 12 1 0 1 0
1  3 1 0 0.96 0.06
1.75  9 1 0 1 0
2.5  5 0.84 0.11 0.58 0.26
5  5 0.72 0.14 0.37 0.15
10  5 0.45 0.11 0.06 0.08
15  3 0.48 0.21 0.04 0.08
30  2 0 0 0 0
Total 44
48 h Cisplatin
0 14 1 0 1 0
0.1  6 0.94 0.07 1 0
0.3  5 1 0 1 0
0.5  6 0.9 0.12 0.88 0.1
1  3 0.94 0.11 0.92 0.13
1.25  6 0.76 0.16 0.75 0.14
1.5  9 0.7 0.09 0.47 0.17
1.75  9 0.44 0.17 0.33 0.1
2  6 0.42 0.16 0.13 0.09
2.5  2 0 0 0 0
3  3 0 0 0 0
5  3 0 0 0 0
Total 72
96 h Cisplatin
0 15 0.64 0.21 0.83 0.11
0.03  3 0.39 0.05 0.85 0.15
0.1  11 0.63 0.17 0.86 0.15
0.3  3 0.43 0.36 0.41 0.16
0.5  7 0.38 0.07 0.61 0.24
1  6 0.34 0.2 0.09 0.07A. Tropitzsch et al. / Toxico
nd with Cisplatin at 1.75 g/ml, the EC50 for OHC determined in
he above described experiments.
.5. Visualization of cochlear hair cells
After termination of the culture period, inner ear whole organ
xplants were ﬁxed with phosphate-buffered formaldehyde solu-
ion 4% (Roti®-Histoﬁx 4%, Karlsruhe, Germany). The organ of Corti
as micro-dissected as a whole mount preparation and divided
nto basal, middle, and apical segments. The surface morphology
f the organ of Corti, in particular hair cell stereocilia bundles,
ere visualized by phalloidin labelling of F-actin and immunohis-
ochemical labelling for myosin VIIa. For immunohistochemistry,
fter a blocking step with 1% BSA in 0.2% Triton PBS, whole mount
reparations were incubated overnight at 4 ◦C with a primary
ntibody for myosin VIIa, 1:500 (rabbit polyclonal, No: PTS-25-
790; Axxora, Proteus Biosciences, Ramona CA, USA). After washing
ith 0.2% Triton/PBS, primary antibodies were detected using
lexa-conjugated secondary antibodies for 60 min  at RT 1:400
Alexa488 donkey anti rabbit, No.: A21206; Molecular Probes,
ife TechnologiesTM, Darmstadt, Germany). The whole mount
reparations were counterstained and incubated with phalloidin
onjugated to the dye Alexa568 (Life TechnologiesTM, Darmstadt,
ermany) for 20 min  in the dark at room temperature. After wash-
ng with 0.2% Triton in PBS specimens were incubated in DAPI
Sigma–Aldrich, St. Louis, USA) diluted 1:100 in PBS for 20 min.
fter a washing step in PBS, the whole mount specimens were
ounted using FluorSaveTM (Calbiochem, Merck KGaA, Darmstadt,
ermany).
.6. Quantiﬁcation of cochlear sensory hair cell maintenance and
tatistical analysis
Quantiﬁcation of surviving and lost sensory hair cell was per-
ormed for control, ototoxic and otoprotective conditions. The
ffects of these experimental paradigms were quantiﬁed in the
hole mount preparations of the organ of Corti. The whole
ount preparations were analysed using a Zeiss Axioplan 2 epi-
uorescence microscope and AxioVision Imaging Software (Zeiss,
öttingen, Germany).
The inner hair cells (IHC) and outer hair cells (OHC) were evalu-
ted separately. Length measurements (mm)  along the longitudinal
xis of the organ of Corti were made in the midline between the
nner and outer hair cell area corresponding to the pillar cell region
or the total of all segments. The level of hair cell preservation
as deﬁned as the percentage of the length in the corresponding
egments with more than 90% hair cells preserved, separately for
nner and outer hair cells. All values of length measurements are
resented as mean ± SD. Differences between experimental groups
ere assessed using JMP  (Version 9; SAS Institute, Cary, USA).
aired Student’s 2-tailed t-test were used (*p < 0.05, **p < 0.01 and
**p < 0.001 values were considered signiﬁcant). SigmaPlot (Ver-
ion 8, Systat Software Inc., San Jose, USA) was used to ﬁt a typical
ose–response curve (four parameter logistic curve) with a variable
lope parameter to obtain a median effective concentration (EC50):
 = min  + max  − min
1 + 10(logEC50−x)·Hillslope
(1)
min: bottom of the curve; max: top of the curve; x: cisplatin
oncentration; EC50: median effective concentration; Hillslope:
haracterizes the slope of the curve at its midpoint..7. Quantiﬁcation of utricle sensory hair cell maintenance
The surface morphology of the utricle, in particular hair
ells, were visualized by phalloidin labelling of F-actin and2  6 0.04 0.07 0 0
Total 51
immunohistochemical labelling for myosin VIIa. Immunohisto-
chemistry was  performed similarly as for the cochlea. Hair
cells were counted using ImageJ (Schneider et al., 2012)
and the ITCN Plugin (Image-based Tool for Counting Nuclei,
http://www.bioimage.ucsb.edu/).
3. Results
3.1. General morphology
Hair cell damage and hair cell loss were observed in whole
organ inner ear explants under simulated microgravity culture
conditions after exposure to cisplatin for 24, 48 and 96 h. The
concentration-dependent effect of cisplatin on hair cells was  com-
pared to control cultures without cisplatin exposure. Evaluation of
the surface morphology of the organ of Corti using F-actin stain-
ing and immunohistochemical labelling with the hair cell marker
myosin VIIa revealed a basal to apical gradient of hair cell loss
(Fig. 1). Increasing cisplatin concentrations resulted in the progres-
sion of hair cell loss in a longitudinal gradient from the cochlear
base towards the cochlear apex and in a radial gradient from outer
hair cells to inner hair cells.
3.2. Dose response curves for cisplatin induced hair cell lossEffects of cisplatin exposure in microgravity culture were quan-
tiﬁed using whole mount preparations of the organ of Corti. Control
groups were compared to cisplatin exposure groups with differ-
ent concentrations and durations of exposure. Table 1 shows the
206 A. Tropitzsch et al. / Toxicology Letters 227 (2014) 203–212
Fig. 1. Photomicrographs of whole mounts of the apical, middle and basal turn (rows) of the cochlea of postnatal day 7 mice after 48 h in microgravity culture conditions.
Preservation of hair cells is shown by F-actin staining with ﬂuorescence-labelled phalloidin (red) and Myosin VIIa F-actin staining (green). Inner ears were treated with
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/ml cisplatin, hair cells in the base being completely wiped out and fully preserved
2.5 g/ml and an exposure time of 24 h, above 1.25 g/ml and an
exposure time of 48 h and above 0.5 g/ml and an exposure time
of 96 h as compared to the untreated controls. Inner hair cell loss
was statistically signiﬁcant (p < 0.05) for all cisplatin concentrations
HC, lower row) and different culture durations (left: 24 h, middle: 48 h, right: 96 h).
e culture medium (data not shown). Function regression lines were obtained using
e indicates 50% hair cell preservation.
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HC. Vertical lines represent the standard error of the EC50 values.
bove 5 g/ml and an exposure time of 24 h, above 1.25 g/ml and
n exposure time of 48 h and above 0.1 g/ml and an exposure time
f 96 h compared to the untreated controls. Complete outer hair cell
oss was found at a concentration of 10 g/ml and an exposure time
f 24 h while complete inner hair cell loss was achieved at 30 g/ml
nd an exposure time of 24 h. Much lower concentrations at and
bove 2.5 g/ml were needed to induce complete outer and inner
air cell loss at an exposure time of 48 h. After 96 h of cisplatin
xposure complete inner and outer hair cell loss was observed at
nd above a concentration of 2.0 g/ml. At this prolonged culture
uration some spontaneous loss of IHCs (preservation 64%; SD 21%)
nd OHCs (preservation 83%, SD 11%) was also observed in the basal
egment under control conditions without cisplatin (Table 1).
Dose–response curves were calculated for inner and outer hair
ells and different exposure times; loss of hair cells was normalized
o the control data obtained without cisplatin (Fig. 2). For the 24 h
xposure time EC50 values were calculated as 8.34 g/ml for the
nner hair cells and 3.20 g/ml for the outer hair cells. In the 48 h
xposure group EC50 values were reduced to 1.77 g/ml for the
nner hair cells and to 1.52 g/ml for the outer hair cells. In the 96 h
xposure group EC50 values were further reduced to 0.80 g/ml
or the inner hair cells, and 0.97 g/ml for the outer hair cells. For
he outer hair cells, doubling the exposure time resulted in approxi-
ately halve the EC50, for the inner hair cells doubling the exposure
ime resulted in approximately a quarter the EC50 (Fig. 3).
We  examined the utricles of ears exposed 48 h to a dose of
.75 g/ml cisplatin and unexposed negative controls (Supplemen-
al Fig. 1A and B). Hair cell counts were in the order of previous
eports (Li et al., 2008) and revealed no signiﬁcant (t-test: p = 0.93)
air cell loss with this exposure parameter. In control (n = 6)
onditions 3040 ± 634 hair cells were counted, after exposure to
.75 g/ml Cisplatin (n = 5) 3069 ± 421 hair cells (Supplemental Fig.
C). This is not unexpected for 1.75 g/ml Cisplatin as signiﬁcant
air cell loss was previously (Cunningham and Brandon, 2006) only
een at a more than 10 fold concentration (20 and 25 g/ml cis-
latin)..3. Culture duration and cisplatin dose
To test if the reduction of the EC50 was predominantly a dose-
r duration-dependent effect, in an additional set of experimentstters 227 (2014) 203–212 207
cisplatin was added to the medium for an initial culture period of
24 or 48 h and was then removed (Fig. 4). These explants were con-
tinued in culture for a subsequent culture period without cisplatin
for an additional 72 or 48 h, respectively. In both cases the total
culture time summed up to 96 h. Cisplatin concentrations used for
these experiments were 0.5 and 1 g/ml and were based on the
EC50 values generated with the 96 h exposure time as described
above. After initial culture periods of 24 and 48 h only a minor hair
cell loss was  observed. However, a progressive loss of hair cells
was seen after completion of the 96 h total culture time despite the
removal of cisplatin from the culture medium during the second
time intervals. Surprisingly, no difference was seen between
samples that had been exposed to cisplatin for the entire culture
period of 96 h using the same concentrations. Obviously, the initial
cisplatin concentration appeared to determine the degree of hair
cell loss irrespective of the duration of the exposure in this setting.
3.4. Otoprotection
In order to validate the use of the culture system for the evalua-
tion of otoprotective compounds the otoprotective agent N-acetyl
l-cysteine (l-NAC, at 0.1, 0.3, 1 (n = 17 each) and 3 mM,  n = 12) was
co-administered with cisplatin (1.75 g/ml) for 48 h (Fig. 5) in an
additional set of experiments. A dose–response curve was calcu-
lated between 0.1 and 3 mM l-NAC. In this set of experiments OHC
preservation was 92% (n = 25, SD: 18%) in the untreated explants
(0 g/ml Cisplatin, 0 mM l-NAC). In the 1.75 g/ml cisplatin treated
explants OHC preservation dropped to 45% (n = 25; SD 25%). These
results correspond to the values determined in the ﬁrst set of exper-
iments. In 1.75 g/ml cisplatin plus 1 or 3 mM l-NAC co-treated
explants OHC preservation was quantiﬁed as 80% (SD: 20%) and
88% (SD: 22%) respectively, which is a highly signiﬁcant (T-test:
p < < 0.001) preservation of outer hair cells when compared to the
1.75 g/ml cisplatin treated cultures. Co-treatment of 1.75 g/ml
cisplatin with 0.1 or 0.3 mM l-NAC did not result in a signiﬁcant
rescue of OHC. Under these experimental conditions the EC50 for
l-NAC was  determined to be 0.70 (± 0.29) mM for the OHC.
As expected from the ﬁrst set of experiments, treatment with
1.75 g/ml Cisplatin resulted in IHC-preservation being higher
(81%, SD: 19%) than in OHCs. A rescue effect to 90% was nevertheless
also seen in the treatments with 1 or 3 mM,  though not signiﬁcant.
4. Discussion
The present observations extend our previous studies (Arnold
et al., 2010; Hahn et al., 2008) of a whole organ culture system of the
inner ear using a rotating bioreactor in “simulated microgravity” to
cisplatin ototoxicity and otoprotection. We  demonstrate that hair
cell loss can be induced by cisplatin in a dose-dependent fashion.
Furthermore, hair cell loss can be prevented by the use of an oto-
protective agent. The ﬁndings show that outer hair cells are more
susceptible than inner hair cells, and hair cells in the base of the
cochlea are more susceptible than hair cells in the apex. It is a gen-
eral observation that the base of the cochlea is more vulnerable to
traumatic insults than the apex as seen in the pattern of hair cell
damage by cisplatin or aminoglycosides (Richardson and Russell,
1991; Rybak, 2007). In the organ culture system employed here this
differential susceptibility is maintained. This suggests an intrinsic
difference in sensitivity of the hair cells to cisplatin along a basal to
apical gradient as the complete perilymphatic space is accessible to
the drug. This effect may  be explained by lower levels of the antiox-
idant glutathione in the cochlear base, which might result in the
accelerated death of basal outer hair cells due to free-radicals (Sha
et al., 2001). This is in agreement with an intrinsic susceptibility to
free radicals that differs among cochlear cell populations.
208 A. Tropitzsch et al. / Toxicology Letters 227 (2014) 203–212
Fig. 4. Preservation of inner (IHC) and outer hair cells (OHC) at 0.5 g/ml (left) and 1 g/ml (right) cisplatin and different combinations of cisplatin exposure time and culture
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turation. Using 0.5 g/ml (A) and 1 g/ml (B) cisplatin at a culture duration of 48 h
n  a marked reduction of preserved hair cells. This reduction remained constant, reg
72  and 48 h respectively).
Several mammalian models have been devised and applied to
he study of cisplatin ototoxicity. These models include cell culture
odels using cell lines derived from the organ of Corti, tissue
ulture dissected from the postnatal inner ear and organ cultures
rom embryonic stages. The conditionally immortalized organ of
orti derived cell lines UB/OC-1 and UB/OC-2 (Rivolta et al., 1998),
C-k3 (Kalinec et al., 1999) and HEI-OC1 (Kalinec et al., 2003) were
stablished from the H-2Kb-tsA58 (Immortomouse) transgenic
ice (Jat et al., 1991).
The UB/OC-1 cells were used to study cisplatin induced ototox-
city and otoprotection (Kaur et al., 2011; Mukherjea et al., 2010;
ig. 5. Protection of outer hair cells (OHC) treated with cisplatin (1.75 g/ml) and l-NAC
he  apical, middle and basal turn (rows) of the cochlea of postnatal day 7 mice after 48 h
taining with ﬂuorescence-labelled phalloidin (red) and Myosin VIIa F-actin staining (gr
air  cell structure due to the addition of l-NAC. (B) Dose response curve for otoprotectiv
oss  induced by cisplatin (1.75 g/ml). Small effects were seen at 0.3 mM l-NAC, while a
alues  of the different experimental conditions are given by diamonds, vertical lines repre
alues  on the x-axis are randomly scattered around the respective value of l-NAC concen
hown to the left; positive control conditions without Cisplatin and without l-NAC are s
he  1.75 g/ml Cisplatin treatment. The continuous curve shows the nonlinear function rell preservation was  almost complete. Extending culture duration to 96 h resulted
ss of the removal of the cisplatin after 24 or 48 h for the remaining culture duration
Mukherjea et al., 2011; Mukherjea et al., 2008), recently reviewed
by Rybak et al. (2012). In these experiments using the UB/OC-1
cell line a cisplatin concentration of 2.5–10 M (0.8–3.3 g/ml) was
used. The OC-k3 cell line was  also used to study cisplatin induced
ototoxicity (Bertolaso et al., 2001; Low et al., 2010; Previati et al.,
2007; Previati et al., 2004). Cisplatin concentrations that effectively
induced cell death in the OC-k3 cell line after 48 h incubation ranged
from 1.7 M (0.5 g/ml) (Low et al., 2010) to 50 M (15 g/ml). The
HEI-OC1 cell line was the most extensively utilized cell line in cis-
platin induced ototoxicity and otoprotection experiments (Altun
et al., 2014; Chen et al., 2012; Choi et al., 2011a,b; Im et al., 2010;
 (1 mM)  in the inner ear culture system. (A) Photomicrographs of whole mounts of
 in microgravity culture conditions. Preservation of hair cells is shown by F-actin
een). The comparison to the middle panel of Fig. 1 exempliﬁes the well preserved
e effects of l-NAC at 0.1, 0.3, 1 and 3 mM concentrations on outer hair cell (OHC)
dding l-NAC at 3 mM resulted in complete protection of the outer hair cells. Mean
sent one standard deviation. For better visibility of experimental results (full dots),
trations. Negative control conditions with 1.75 g/ml Cisplatin without l-NAC are
hown to the right. The broken lines indicate the EC50 value for l-NAC as related to
egression line of a logistic function type (Eq. (1)).
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eong et al., 2011; Kim et al., 2006, 2009, 2010, 2011; Lee et al.,
011; Myung et al., 2011; Oh et al., 2011; Park et al., 2012; So et al.,
008; Yu et al., 2010; Shin et al., 2012). In these studies cisplatin
oncentrations of 10–20 M (−3 to 6 g/ml) led to cell death of
bout 50% of the cells after exposure times to cisplatin ranging
rom 24 to 72 h. However, quantitative data concerning dose– (or
ime–) response data can be extracted from only a limited num-
er of reports: 50% viability was reported after 21 h incubation
sing 20 M (6 g/ml) cisplatin (Kim et al., 2010); 50% viability
as reported after 55 h incubation using 20 M (6 g/ml) and after
6 h incubation using 40 M (13 g/ml) (Im et al., 2010). An EC50
f 3.3 M (1 g/ml) at 24 h exposure to cisplatin can be extracted
rom a dose–response curve in a recent report (Lee et al., 2011). This
atter value is about an order of magnitude lower when compared
o the previous reports (Im et al., 2010; Kim et al., 2010). In sum-
ary, after 24 h cisplatin incubation the 50% cell viability data from
EI-OC1 cell line reported are in the range of 3–20 M (1–6 g/ml).
Tissue cultures prepared from the postnatal rat inner ear were
lso applied to study cisplatin ototoxicity. In these rat tissue culture
tudies cisplatin concentrations had a similar range as the con-
entrations used in the organ culture system of the present study
Cheng et al., 1999; Coling et al., 2007; Du et al., 2011; Kim et al.,
009; Kopke et al., 1997; Liu et al., 1998; Park et al., 2009; Yarin
t al., 2005; Zhang et al., 2003; Zheng and Gao, 1996). In summary,
n these studies a hair cell loss of 50% was observed at cisplatin
oncentrations of 15–30 M (5–10 g/ml) at an exposure time of
4 h (see Supplemental Table 1 for details). In summary, after 24 h
isplatin incubation the 50% cell viability data from tissue culture
xperiments from the rat organ of Corti reported are in the range
f 16–33 M (5–10 g/ml).
In experiments performed in vivo, different regimes with either
ingle or multiple cisplatin applications were used (Supplemental
able 2). In guinea pigs the dosages in single applications ranged
rom 5 to 20 mg/kg (Fleischman et al., 1975; Kopecky et al., 2012;
ee et al., 2011; Xiong et al., 2011; Yin et al., 2009) with signif-
cant hearing loss and hair cell deletion at dosages of 10 mg/kg
Daldal et al., 2007; Murphy and Daniel, 2011; Ramirez-Camacho
t al., 2008; Wang et al., 2004; Yin et al., 2009) and above. Dosages
bove 14 mg/kg showed an increasing lethality. In guinea pigs the
totoxic dosages in multiple applications start from 1.5 mg/kg/day
Sepmeijer and Klis, 2009; Stengs et al., 1998) for 6 up to 22 consec-
tive days (until hearing loss was observed). Higher dosages were
lso used, 3 mg/kg/week for up to 8 weeks (Nader et al., 2010; Saliba
t al., 2010) and up to 10 mg/kg/day for 2 days (Choe et al., 2004).
n female Fisher344 rats two, four-day cycles of cisplatin (2 mg/kg),
eparated by a 10-day rest were applied to induce an ototoxic effect
Guthrie et al., 2008), resulting in a moderate hearing loss of 15 dB. A
ingle dose of 16 mg/kg resulted in a more severe hearing loss of up
o 70 dB and complete OHC loss in the cochlear base (Campbell et al.,
996; Kamimura et al., 1999). Single doses of 11–13 mg/kg cisplatin
esulted in 20–40 dB hearing loss and a 50–60% loss or damage of
air cells (Kapusuz et al., 2013; Kaur et al., 2011; Mukherjea et al.,
010; Mukherjea et al., 2008; Mukherjea et al., 2006). In a long
erm study 7 mg/kg led to an additive interaction between cisplatin
toxicity and age-related hearing loss (Bielefeld, 2013).
Compared to rat and guinea pig (Adams, 2002) the inner ear of
ice appears the least sensitive to cisplatin in vivo. Using a single
ose of 16 mg/kg i.p. (Kim et al., 2009; Parham, 2011) or appli-
ation of a four-day 4 mg/kg (per day) regime (Oh et al., 2011;
ark et al., 2009) or 2 times 5 mg/kg (Oh et al., 2011) resulted in
nly moderate hearing loss of about 20 dB. Using a single dose of
0 mg/kg i.p. cisplatin (Kopecky et al., 2012), hearing loss up to
5 dB in the mid-frequency range was achieved. Using the same
ose, high-frequency loss and outer hair cell loss was observed 72 h
ollowing treatment (Schmitt and Rubel, 2013). To conclude, as a
ough estimate, an in vivo ototoxic effect was observed between 10tters 227 (2014) 203–212 209
and 20 mg/kg either as a single or cumulative cisplatin dose. Assum-
ing an equal distribution within the body, this corresponds to a
dosage of 10–20 g/ml (approx. 30–60 M),  which is well within
the range used in vitro studies utilizing cochlear derived cells. A
recent in vivo pharmacokinetic study of cisplatin in the guinea pig
demonstrated that a single dose of 8 mg/kg body weight of cisplatin
applied intravenously resulted in an early high concentration of
cisplatin in the base of the cochlea and a delayed elimination of
cisplatin from the scala tympani perilymph compared to blood. At
1 h after the application the levels of cisplatin in perilymph and
blood were equivalent at a concentration of approx. 6 M (cor-
responding to approx. 2 g/ml) and further decreased thereafter
(Hellberg et al., 2013). In summary, this result indicates that in vivo
a single ototoxic dose of systemic cisplatin of 8 mg/kg results in
perilymphatic cisplatin concentration of 6 M (2 g/ml) in which
is well in the range of mammalian in vitro preparations, as men-
tioned above are 3–20 M (1–6 g/ml) for cell lines and 15–33 M
(5–10 g/ml) for tissue culture explants. In the organ culture sys-
tem of the present study the ototoxic effect on the outer hair cells
had an EC50 value of 11.5 M (3.50 g/ml) at 24 h cisplatin expo-
sure decreasing to 5 M (1.52 g/ml) for 48 h exposure time, also
appears close to the in vivo situation and other mammalian in vitro
models.
Moving to the human situation and considering the long half-
life of cisplatin in humans (long term elimination: 327 ± 91 h
(Monjanel-Mouterde et al., 2003), this may  also roughly represent
the concentration recommended for use in humans (50–120 mg/m2
BSA; average BSA 1.9 m2 ≈ 70 kg; 50 mg  · 1.9 per 70 kg = 1.4 mg/kg;
120 mg  · 1.9 per 70 kg = 3.3 mg/kg). Although varying considerably,
average peak plasma concentrations between 1.7 up to roughly
10 g/ml (6–33 M)  were observed (Vermorken et al., 1986) after
infusion of 100 mg/m2 cisplatin. In patients receiving high dose cis-
platin (150–225 mg/m2), 100% of patients showed hearing loss in
the very high frequencies above 9 kHz (Kopelman et al., 1988). If an
average of 70 kg body weight is assumed, this high dose cisplatin
regime would correspond to 4–6 mg/kg which is in the range of
ototoxic dosage in experimental animals (supplemental Table 2).
A cumulative cisplatin dose of over 400 mg/m2 resulted in hear-
ing loss in more than 50% of patients (Bokemeyer et al., 1998). In a
recent retrospective analysis of 102 pediatric patients 81.7% of the
patients developed hearing loss after a mean cumulative cisplatin
dose of 417.7 mg/m2 (Yancey et al., 2012). In summary, the cis-
platin concentrations obtained to be toxic to hair cells in the current
study are well within the range of other in vitro and in vivo stud-
ies as well as the range of concentrations that are used in clinical
applications.
A non-mammalian model to study cisplatin ototoxicity, a larvae
zebraﬁsh lateral line model, has been introduced (Ou et al., 2007;
reviewed in (Brack and Ramcharitar, 2012; Buck et al., 2012; Cofﬁn
et al., 2010; Hirose et al., 2011b; Ou et al., 2010). The model shows
evidence of dose-dependent cisplatin induced hair cell loss. The
zebraﬁsh larvae are available in large numbers and access to hair
cells on the body surface lateral line allows screening in alive ani-
mals (Buck et al., 2012; (Shin et al., 2013; Shin et al., 2012). However,
the cisplatin dosages applied to achieve hair cell loss are consider-
ably higher (1–2 orders of magnitude; up to 1000 M ≈ 300 g/ml)
than the cisplatin dosages required in the mammalian models men-
tioned above and the exposure times are considerably lower (in
the range of several hours) than in mammalian in vitro and in vivo
models (Buck et al., 2012; Hong et al., 2013; Ou et al., 2007).
Since biological effects of drugs may  be different at low and
high dosage, interpreting results from the zebraﬁsh model may
require some caution. It is argued (Ou et al., 2007) that the use
of a much shorter exposure time in the zebraﬁsh (several hours)
require higher doses of cisplatin and simply result in an earlier
initiation of a cell death cascade (Ou et al., 2007). Combining the
210 A. Tropitzsch et al. / Toxicology Le
Fig. 6. Compiled data of 50% effect on hair cells in different experimental conditions
as  indicated in the legend. Regression analysis using a power law function (f(x) = axk)
on  these data plotted on a log–log scale. The regression-analysis resulted in a straight
line. This common nonlinear dependency between exposure time and EC50 across
the species indicates a common mechanism in damaging hair cells in lateral line of
zebraﬁsh and hair cells in mouse. Data for HEI-OC1 were taken from: Chen et al.,
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t012; Im et al., 2010; Lee et al., 2011; Kim et al., 2010. Data for rat explants were
aken from: Kopke et al., 1997; Zheng and Gao, 1996; Zhang et al., 2003. Data from
ebraﬁsh lateral line stem from Ou et al. (2007).
C50-data on hair cell loss from the zebraﬁsh (Ou et al., 2007) and
he EC50-data obtained in the present study on the loss of OHCs as
ell as representative studies from inner ear cell lines and tissue
ulture supports this hypothesis. A power law function (f(x) = axk)
s adequate to ﬁt the combined data (Fig. 6). On a log–log plot the
egression-line results in a straight line, where the slope of the line
s equal to the power exponent k (because log(f(x)) = k*log(x) + a).
his common nonlinear dependency between exposure time and
C50 across the species and methods indicates a common mech-
nism in damaging hair cells from the lateral line and the organ
f Corti in vitro and in vivo. However, this does not exclude
hat different pathways are initiated in mammals and zebraﬁsh;
oreover in zebraﬁsh the lowest toxic cisplatin concentration
50 M = 15 g/ml) is still above the concentration used in most
ammalian in vitro studies excluding a direct comparison under
he same parameters. In this regard the different mechanism of
poptotic or necrotic cell death have to be considered. The pri-
ary biological target of cisplatin is DNA (reviewed in: Jamieson
nd Lippard, 1999; Langer et al., 2013; Wang and Lippard, 2004).
ubsequently cell death may  occur via several, complex signalling
athways (reviewed in Rybak et al., 2009). In a study on primary cul-
ures of mouse proximal tubular cells apoptotic versus necrotic cell
eath is dependent on the cisplatin concentration (Lieberthal et al.,
996), high concentrations of cisplatin (800 M)  led to necrotic cell
eath in an exposure time of 4 h while much lower concentrations
f cisplatin (8 M)  led to apoptosis over an exposure time of 4 days.
urthermore, this study concludes that reactive oxygen species
lay a role in mediating apoptosis but not necrosis. This notion
erived from a kidney cell line is supported by the recent ﬁnding
hat HEI-OC1 auditory cells treated with 20 M (6 g/ml) cisplatin
ncreased the production of intracellular ROS and cell death in a
ime-dependent manner of treatment (Chen et al., 2012; Kim et al.,
010). Considering further differences between the mammalian
nd the ﬁsh model is the lack of compartmentalization of inner
ar ﬂuids in ﬁsh. Also there are no outer and inner hair cells in
he neuromast. Furthermore spontaneous regeneration of hair cellstters 227 (2014) 203–212
in the lateral line occurs within 24–72 h (Mackenzie and Raible,
2012) prohibiting the 24–96 h time windows of exposure used in
mammalian in vitro systems. Consequently results from zebraﬁsh
screening efforts need to be conﬁrmed and validated in mammalian
models.
In conclusion, the proposed whole organ model allows cul-
turing the intact postnatal mammalian inner ear sufﬁciently long
to observe relevant cell biological processes in cisplatin induced
ototoxicity and its protection by an antioxidative agent. Pharma-
cological studies can be performed in dose ranges comparable to
other mammalian in vitro and in vivo models and in the range of
concentrations, which are used therapeutically in humans. Though
performed in vitro, this whole organ ototoxicity and otoprotection
assay of the postnatal ear preserve the structure of the organ and
most closely resembles the in vivo situation.
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